摘要
目的探讨细胞角蛋白19片段抗原21-1(Cyfra21-1)检测在宫颈癌新辅助化疗疗效评价中的作用。方法应用电化学发光法检测53例健康人、60例CIN1-3级患者、56例宫颈癌患者血清Cyfra21-1和对需行新辅助化疗的44例宫颈癌患者化疗前后的血清Cyfra21-1进行比较。结果宫颈癌患者的血清Cyfra21-1与健康人、CIN1-3患者血清Cyfra21-1值的差异有统计学意义(P<0.05),但健康人与CIN1-3患者血清Cyfra21-1值的差异无统计学意义(P>0.05);化疗前后血清Cyfra21-1值有统计学意义(P<0.05);化疗后肿块缩小的程度与血清Cyfra21-1下降程度有统计学意义,血清Cyfra21-1下降50%,表明肿块缩小至少25%。结论血清Cyfra2-1的检测对评价宫颈癌患者新辅助化疗效果具有肯定的临床意义。
Objective To investigate the role of the cytokeratin 19 fragment antigen 21-1 （ Cyfra21-1 ） level detection in the evaluation of cervical cancer new adjuvant chemotherapy. Methods Serum Cyfra21-1 level was detected in 53 healthy adults and 60 cases of CIN1-3 and 56 cases of cervical cancer by chemiluminescence immunoassay and the serum Cyfra21-1 level in 44 cases of cervical cancer by neo-adjuvant chemotherapy was compared before and after chemotherapy. Results There were significant differences between serum Cyfra21-1 level in cervical cancer and serum Cyfra21-1 levels in healthy people and CIN 1-3 cases （P〈 0.05 ）, and no significant difference in serum Cyfra21-1 level between the healthy people and CIN1-3 cases（P〉0.05）. There was a significant difference in serum Cyfra21-1 level before chemotherapy compared With post-chemotherapy serum Cyfra21-1 level（P〈0.05）. There was a significant difference between post-chemotherapy tumor size and serum Cyfra21-1 level. When serum Cyfra21-1 level decreased by 50% ,the tumor size shrunk by at least 25%. Conclusion The serum Cyfra2-1 level detection is of great value in evaluating cervical cancer neoadjuvant chemotherapy.
出处
《中国现代医生》
2010年第15期5-6,共2页
China Modern Doctor
